A Canadian Laboratory-Based Retrospective of the 2024/2025 Influenza Season: Monitoring the Impacts of Influenza Evolution on Viral Antigenicity and Antiviral Susceptibility.
Ranadheera Charlene C, Gao Ruimin R, Buchanan Cody C, Frost Jasmine J et al.
Seasonal influenza affects thousands of Canadians each year and places significant strain on workplaces and the health systems. Robust laboratory-based surveillance is essential to monitor viral evolution and evaluate the suitability of medical countermeasures. The Canadian Influenza Surveillance Program characterizes circulating influenza viruses to determine genetic clades, monitor evolutionary trends, assess antigenicity and vaccine strain relatedness, and evaluate susceptibility to neuraminidase inhibitors. Methods include whole genome sequencing, hemagglutination inhibition assays, and neuraminidase inhibition assays. From September 1, 2024 to August 31, 2025, the program antigenically characterized 1563 influenza isolates identified and submitted by Canadian laboratories. Of these, 99.4% of influenza A/H1N1, 86.6% of influenza A/H3N2, and 100% of influenza B isolates were antigenically related to their respective component of the 2024-2025 Northern Hemisphere vaccine. Genetic analysis of influenza A/H3N2 isolates identified three distinct mutation clustering patterns associated with reduced antigenic reactivity to the vaccine strain. Additionally, 1567 influenza viruses underwent antiviral susceptibility testing. Eleven influenza A/H1N1 isolates showed reduced inhibition to oseltamivir and two to zanamivir, all containing known resistance-associated markers. These findings highlight the importance of comprehensive virological assessment, integrating genotypic and phenotypic data, to inform annual vaccine strain selection and support clinical decision-making.